Brightline-1: Phase II/III trial of the MDM2–p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS Review

  

Authors:	Schöffski, P.; Lahmar, M.; Lucarelli, A.; Maki, R. G.
Review Title:	Brightline-1: Phase II/III trial of the MDM2–p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS
Journal Title:	Future Oncology
Volume:	19
Issue:	9
ISSN:	1479-6694
Publisher:	Future Medicine
Date Published:	2023-03-01
Start Page:	621
End Page:	629
Language:	English
DOI:	10.2217/fon-2022-1291
PROVIDER:	EBSCOhost
PROVIDER:	cinahl
PUBMED:	36987836
DOI/URL:	https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=cin20&AN=163601396&authtype=sso&custid=s2915669&site=ehost-live&scope=site&custid=s2915669
Notes:	Accession Number: 163601396 -- Entry Date: In Process -- Revision Date: 20230511 -- Publication Type: Article -- Journal Subset: Biomedical; Europe; UK & Ireland -- NLM UID: 101256629. -- Source: Cinahl

https://synapse.mskcc.org/synapse/works/has_related_data_chk/206926